Atlas Trials

Meningococcal Vaccine

12 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Meningococcal Vaccine

RecordFirmDate
Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age (NCT04893811)Pfizer2021-08-18
Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age (NCT04819113)Pfizer2021-04-09
A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants (NCT04645966)Pfizer2020-11-26
MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age (NCT04440163)Pfizer2020-06-17
A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules (NCT04440176)Pfizer2020-06-17
Non Inferiority Trial of Locally Manufactured Meningococcal ACWY Vaccine 'Ingovax ACWY' in Bangladesh. (NCT03263403)International Centre for Diarrhoeal Disease Research, Bangladesh2017-08-21
A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age. (NCT03135834)Pfizer2017-04-24
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years (NCT01830855)Pfizer2013-04-01
A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years. (NCT01323270)Pfizer2011-03-18
A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years (NCT01299480)Pfizer2011-03-03

Track Meningococcal Vaccine automatically

Every clearance here is in the API, with alerts when new ones post.